<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01435291</url>
  </required_header>
  <id_info>
    <org_study_id>11-PP-07</org_study_id>
    <nct_id>NCT01435291</nct_id>
  </id_info>
  <brief_title>AADAPT - Analysis of Advagraf Dose Adaptation Post Transplantation</brief_title>
  <acronym>AADAPT</acronym>
  <official_title>Prospective Pharmacokinetic and Pharmacogenetic Analysis of Advagraf After Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pharmacokinetics and pharmacogenetics study to complement the current knowledge of
      tacrolimus prolonged release (Advagraf®) in the immediate post-transplantation period and at
      steady-state (M3 post transplantation) and to improve the optimal dose of Advagraf® based on
      tacrolimus AUC estimated by two Limited Samples Strategies during the first 3 months after
      renal transplantation.

      Data obtained with tacrolimus prolonged release will be compared with those of tacrolimus
      immediate release (Prograf®)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicentre open-labeled randomized pharmacokinetic (PK) and pharmacogenetic (PG) study to
      compare Advagraf and Prograf immediate post-transplantation (Day 8) and steady-state (Day 84)
      systemic exposure.

      Tacrolimus PK profile, tacrolimus systemic exposure assessed by Limited Samples Strategies
      (LSS) (i.e.: Bayesian estimators (BE) and Multilinear Regressions (MLR)), and impact of
      CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus PK will also be determined to improve
      the optimal dose of Advagraf® for kidney transplant patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC 0-24h of tacrolimus at Day 8 and Day 84</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC 24h of tacrolimus using limited samples strategies (LSS) at Day 8 and Day 84</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Renal Transplantation</condition>
  <arm_group>
    <arm_group_label>Advagraf</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Prograf</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Advagraf Capsule</intervention_name>
    <description>Other Names:
FK506E
MR4
tacrolimus modified/prolonged release Drug: MPA Solution for infusion and per os Other Name: Mycophenolate Mofetil or Mycophenolic Acid Drug: Basiliximab IV infusion Other Name: Simulect Drug: Corticosteroids per os Other Name: Methylprednisolone or equivalent</description>
    <arm_group_label>Advagraf</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prograf Capsule</intervention_name>
    <description>Other Names:
FK506E
MR4
tacrolimus Drug: MPA Solution for infusion and per os Other Name: Mycophenolate Mofetil or Mycophenolic Acid Drug: Basiliximab IV infusion Other Name: Simulect Drug: Corticosteroids per os Other Name: Methylprednisolone or equivalent</description>
    <arm_group_label>Prograf</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult recipients aged between 18 to 70

          -  Primary renal transplantation

          -  Cadaver or living transplantation or living (non HLA identical) donor with compatible
             ABO blood type.

          -  absence of anti-LHA antibodies in lymphocytotoxicity and Luminex

          -  Negative cross-match in cytotoxicity

          -  Negative pregnancy test for female patients of childbearing potential, and agreement
             to practice effective birth control during the study

        Exclusion Criteria:

          -  Combined transplantation

          -  Renal bigraft

          -  History of any other transplantation

          -  Receiving a graft from a non-heart-beating donor.

          -  Requiring ongoing dosing with a systemic immunosuppressive drug prior to
             transplantation

          -  Patient who received within one month prior to study an inductor of CYP50 3A or
             requiring during the study an inhibitor of CYP50 3A or of P-gp.

          -  Significant, uncontrolled concomitant infections and/or severe diarrhoea, vomiting,
             active upper gastro-intestinal tract malabsorption or active peptic ulcer

          -  Subject or donor known to be HIV positive

          -  Active viral hepatitis (VHB, VHC) at randomisation

          -  Known allergy or intolerance to tacrolimus, macrolide antibiotics, corticosteroids, or
             mycophenolate mofetil or any of the product excipients

          -  Diagnosis of new-onset malignancy prior to transplantation, with the exception of
             basocellular or squamous cell carcinoma of the skin which had been treated
             successfully.

          -  Current participation in any other clinical study

          -  Any clinical condition which, in the opinion of the investigator, would not allow safe
             completion of the study

          -  Patient not able to comply with the study procedures

          -  Breast-feeding mother
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabeth CASSUTO, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nice</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Bicêtre</name>
      <address>
        <city>Kremlin Bicêtre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rangueil</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Tours Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2011</study_first_submitted>
  <study_first_submitted_qc>September 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2011</study_first_posted>
  <last_update_submitted>July 28, 2014</last_update_submitted>
  <last_update_submitted_qc>July 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

